Diabetes Core Update21 Okt 2025

Special Edition: The Cardiovascular Outcome Trials – Origin and Perspective

In this special series on The Cardiovascular Outcome Trials our host, Dr. Neil Skolnik will discuss the history and importance of the Cardiovascular Outcome Trials for diabetes medications . In Part 1 we discuss an historical perspective with Dr. Steven Nissen and how this has lead to the CVOTs that change the way we practice from EMPA-REG in 2015 to SURPASS-CVOT in 2025. This special episode is sponsored with support from Lilly.

Presented by:

Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health

Steven Nissen, M.D., Chief Academic Officer of the Heart and Vascular Institute at the Cleveland Clinic and Professor of Medicine at the Clevland Clinic Lerner College of Medicine.

Selected references:

Nissen SE, Wolski K, Topol EJ. Effect of Muraglitazar on Death and Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes Mellitus. JAMA. 2005;294:2581-2586

Kahn SE, Haffner SM, Heise MA, et al. Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy (ADOPT). N Engl J Med 2006;355:242743.

DREAM trial investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006;368:1096

Nissen SE, Wolski K. Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes. N Engl J Med 2007;356:2457-2471.

Det här avsnittet är hämtat från ett öppet RSS-flöde och publiceras inte av Podme. Det kan innehålla reklam.

Avsnitt(100)

Special Edition - Weight Bias and Stigma - Part 2 - Jan 2026

In this special series on Weight Bias and Stigma our host, Dr. Neil Skolnik will discuss weight bias and stigma and its importance because weight bias and stigma have an important impact the experien...

30 Jan 37min

Diabetes Core Update Feb 2026

This issue will review: 1. Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial 2. Impact of Oral Semagluti...

28 Jan 26min

Special Edition - Automated Insulin Delivery - Part 2 - Jan 2026

In this special series on Automated Insulin Delivery our host, Dr. Neil Skolnik will discuss the benefits of Automated Insulin Delivery for people with Type 2 Diabetes. This special episode is support...

13 Jan 41min

Diabetes Core Update Jan 2026

This issue will review: 1. Evolocumab in Patients without a Previous Myocardial Infarction or Stroke 2. SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria 3. ...

5 Jan 26min

Special Edition - Weight Bias and Stigma – Part 1

29 Dec 202538min

Special Edition: What's Next: Adherence to Medications – Challenges and (some) Solutions December 2025

In this special edition on Adherence to Medications our host, Dr. Neil Skolnik will discuss medication adherence and the role of clinicians, pharmacies and pharmacists in helping with medication adher...

18 Dec 202526min

Special Edition: MASH Part 2 – Diagnosis and Treatment – December 2025

In this special series on Metabolic-Dysfunction Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-associated steatohepatitis (MASH) our host, Dr. Neil Skolnik will discuss Epidemiol...

15 Dec 202532min

Special Edition - Automated Insulin Delivery - Part 1

In this special series on Automated Insulin Delivery our host, Dr. Neil Skolnik will discuss with Davida Kruger the benefits of Automated Insulin Delivery for people with Type 2 Diabetes. This special...

9 Dec 202531min